This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: University of Pennsylvania. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Claude Warzecha: Innovator in Tumor Suppression Research
Introduction
Claude Warzecha is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of cancer research, particularly in the area of tumor suppression. His innovative work has led to the development of methods and compositions that utilize splicing regulatory proteins.
Latest Patents
Warzecha holds a patent for "Methods and compositions using splicing regulatory proteins involved in tumor suppression." This patent focuses on the diagnosis and prognosis of mammalian carcinoma or cancer derived from primary epithelial cells and tissue fibrosis. The methods are designed using newly identified epithelial cell-type specific splicing factors, ESRP1 and ESRP2, which play crucial roles in tumor suppression. The diagnostic reagents developed for detecting these splicing factors in nucleotide or protein form are instrumental in these methods. Additionally, therapeutic compositions can provide epithelial cells with these factors to maintain FGFR2 and assist in suppressing metastasis. A high throughput splicing assay to identify compounds that alter splicing events is also described in the patent. Furthermore, RNCP1 is identified as a splicing factor and a diagnostic for conditions characterized by inappropriate FGFR2-splicing.
Career Highlights
Warzecha is affiliated with the University of Pennsylvania, where he continues to advance his research in cancer biology. His work has garnered attention for its potential impact on cancer diagnostics and therapeutics.
Collaborations
He has collaborated with notable colleagues such as John Hogenesch and Russ P Carstens, contributing to a rich environment of innovation and research.
Conclusion
Claude Warzecha's contributions to the field of tumor suppression through his innovative patent highlight the importance of splicing regulatory proteins in cancer research. His work at the University of Pennsylvania continues to pave the way for advancements in cancer diagnostics and treatment.